Synthetic Biologics to Host Microbiome Analyst & Investor Meeting

ROCKVILLE, Md., June 1, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, today announced that the Company is hosting its Microbiome Analyst & Investor Meeting on Wednesday, June 3, 2015, at the Grand Hyatt New York Hotel. Synthetic Biologics will provide an overview of the clinical, regulatory and commercial pathways of the Company’s clinical-stage therapeutics, including SYN-010 to reduce the impact of methane producing organisms on irritable bowel syndrome with constipation (IBS-C), and SYN-004 to protect the gut microbiome from intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection.

The program includes presentations by Synthetic Biologics’ President and Chief Executive Officer Jeffrey Riley and Senior Vice President, Clinical & Regulatory Affairs, Joseph Sliman, M.D., MPH. In addition, keynote speakers, Mark Pimentel, M.D., FRCP(C), Director, GI Motility Program and Laboratory, and Professor of Medicine at Cedars-Sinai in Los Angeles, and Professor Mark H. Wilcox, M.D., FRCPath, Consultant/Head of Microbiology at the Leeds Teaching Hospitals NHS Trust, Professor of Medical Microbiology at the University of Leeds and the Lead on C. difficile Infection, Public Health England (PHE), will discuss Synthetic Biologics’ novel approaches to treating IBS-C and preventing C. difficile.

A live webcast of the presentations will begin on June 3, 2015, at 9:00 a.m. EDT and the webcast is scheduled to conclude by 11:30 a.m. EDT. The live webcast of the event will be available via the internet at: https://tallen.webcasts.com/starthere.jsp?ei=1066312. An archived webcast will be available at the same website following the meeting.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company is developing an oral biologic to protect the gut microbiome from intravenous (IV) antibiotics for the prevention of C. difficile infection and an oral statin treatment to reduce the impact of methane producing organisms on irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis in collaboration with Intrexon Corporation (NYSE: XON), and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS. For more information, please visit Synthetic Biologics’ website at www.therivabio.com.

Logo- https://photos.prnewswire.com/prnh/20130522/MM19465LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/synthetic-biologics-to-host-microbiome-analyst–investor-meeting-300091040.html

SOURCE Synthetic Biologics, Inc.